Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:38 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer
NCT04479436 · Daiichi Sankyo · PHASE2 · terminated · last registry update 2025-05-18 · Colorectal cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated early given the Interim Analysis for Part 1 (signal finding) did not meet pre-specified criteria and will not proceed to Part 2. Sponsor will proceed closing the study.” | Open Targets' class: negative | Registry record, Daiichi Sankyo |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ERBB3 in colorectal cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision